Biotech News

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

Brainstorm Cell Therapeutics Inc. (BCLI)Brainstorm Cell Therapeutics Inc.FDA / regulatory

BCLI (BCLI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bcli.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-11-16 21:01 EST

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

CGTXCognition Therapeutics2026-09-29 11:30 EST

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

CLNNClene Inc.2026-09-21 12:30 EST

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA

ANVSAnnovis Bio2026-11-20 13:00 EST

Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA

TEVATeva Pharmaceutical Industries2026-11-16 13:00 EST

U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults

ECORelectroCore2026-10-28 12:00 EST

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

IKTInhibikase Therapeutics2026-10-20 20:01 EST

Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors

CLNNClene Inc.2026-10-19 12:00 EST

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

Brainstorm Cell Therapeutics Inc.

Autologous Cell-Therapy Developer BrainStorm Cell Therapeutics is developing autologous cellular therapies for neurodegenerative diseases. Its programs use a patient's own cells to deliver neuroprotective and immunomodulatory factors in disorders characterized by progressive neuronal damage. NurOwn Technology NurOwn, also known as...

Recent company news

Stock data

Close
0.84 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States